CBIO Brand Development Inc. is a Vancouver, Canada based HempDerived CBD product company whose manufacturing partner uses a
revolutionary patented pharmaceutical grade ingredient as the base
for all its formulations, for people and their pets. CBIO is currently
commercializing several ailment specific brands for immediate
release into the U.S. wholesale market.
2. This presentation contains "forward looking information" within the meaning of applicable Canadian securities legislation. Wherever
possible, words such as "plans", "expects", or "does not expect", "budget", "scheduled", "estimates", "forecasts", "anticipate" or "does
not anticipate", "believe", "intend" and similar expressions or statements that certain actions, events or results "may", "could", "would",
"might" or "will" be taken, occur or be achieved, have been used to identify forward looking information.
Forward-looking information involves known and unknown risks, uncertainties and other factors which may cause the actual results,
performance or achievements of CBIO Brand Development Inc., to be materially different from any future results, performance or
achievements expressed or implied by the forward-looking information. Although CBIO Brand Development Inc., has attempted to
identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking
statements, there may be other factors that cause actions, events or results not to be as anticipated, estimated or intended. There can be
no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from
those anticipated in such statements.
Forward looking statements are based on the reasonable assumptions, estimates, analysis and opinions of management made in light of
its experience and its perception of trends, current conditions and expected developments, as well as other factors that management
believes to be relevant and reasonable in the circumstances at the date that such statements are made, but which may prove to be
incorrect. Management believes that the assumptions and expectations reflected in such forward-looking statements are reasonable.
This presentation includes market and industry data that has been obtained from third party sources including publications from various
industries, and where appropriate, certain numbers, including dollar amounts, have been rounded out by us to avoid lengthy numbers.
We believe that this industry data is accurate and that its estimates and assumptions are reasonable; however, there are no assurances
as to the accuracy or completeness of this data. Third party sources generally state that the information contained therein has been
obtained from sources believed to be reliable; however, there are no assurances as to the accuracy or completeness of included
information. Although the data is believed to be reliable, we have not independently verified any of the data from third party sources
referred to in this presentation or ascertained the underlying economic assumptions relied upon by such sources.
Forward Looking Information
CBD AT THE CELLULAR LEVEL
3. CBIO Brand Development Inc. is a Vancouver, Canada based Hemp-
Derived CBD product company whose manufacturing partner uses a
revolutionary patented pharmaceutical grade ingredient as the base
for all its formulations, for people and their pets. CBIO is currently
commercializing several ailment specific brands for immediate
release into the U.S. wholesale market.
Company
CBD AT THE CELLULAR LEVEL 3
4. 4
An industry research group's headline of a market study said: "Hemp-Derived
CBD Will Outpace All Other Cannabis Markets, Projected to Hit $22 Billion by
2022 - As the CBD market consolidates, wholesale retailers are expected to
provide exponential growth." The article went on to say: "Right now, online
orders of hemp-derived CBD products are the primary sales driver.
Companies… can ship CBD products anywhere in the U.S., as long as the plant
source meets that legal definition of industrial hemp and includes less than
0.3-percent THC. The trend that (the report) points to, however, is a flip from
mostly retail to mostly wholesale. As these products become normalized in
U.S. wellness markets, the online ordering process--direct to consumer--will
quickly be replaced by a more traditional market that involves wholesale
opportunities“. View Original News Source: http://www.newswire.ca/en/releases/archive/February2019/27/c5387.html
Current Market
CBD AT THE CELLULAR LEVEL
5. Marketing
CBIO has engaged with an industry leading marketing firm with over 100 years of combined
experience with Health, Skin Care, Fitness, and Nutrition brands. The goal for the brand is to raise
brand awareness, create and sustain brand loyalty, and maximize promotional vehicles across
multiple media outlets based on unique key points of differences CBIO brings to the marketplace.
Positioning
To position CBIO products at the top of the list as the choice brand for retailers, health-nutrition
conscious consumers, and as well as for industry editors and reporters.
Awareness
To generate interest and brand awareness. This is a vital step toward creating value for the
company as a whole.
Exposure
To gain creative, positive media exposure. This is a key element to the successful promotion of our
brands. Sample of Media Outlet Targets Include: National & Cable Television Networks, Wire
Services and Websites, Health Radio Programs, Newspapers, Women’s Interest Magazines, Health &
Fitness Magazines and Men’s Magazines
5CBD AT THE CELLULAR LEVEL
6. Distribution
CBIO has engaged with a top National Distribution Agent whose distribution
model offers our brands maximum penetration and speed to market to the
top 100 retail chains in the United States, which covers the top 80 percent of
the core market. Their executive team has in-depth relationships with key
executives that place orders.
This dynamic approach will maximize our brand’s return on investment by
offering parallel distribution with both the online segment and the core
market as mentioned above. This approach provides a fast track to the largest
market in the world.
6CBD AT THE CELLULAR LEVEL
7. Differentiator
➢CBIO’s current product offerings are manufactured using the patented raw
ingredient, GrowthCell ™, combined with Hemp-Derived CBD.
➢This anti-aging raw ingredient contains natural occurring growth factors &
peptides responsible for reprogramming adult stem cells and amino acids in
the body.
➢GrowthCell ™ is a combination of Growth Factors and SUPER antioxidants
known as oligopeptides. Combining these two properties, GrowthCell ™ has
the capability of cell rejuvenation and increased cellular signalling along with
the reduction of free radicals in the body.
7CBD AT THE CELLULAR LEVEL
8. GrowthCell + CBD
The Problem
A major hurdle that faces the CBD market in North America is 100% absorption of CBD without any trace of THC.
It is a known problem that for CBD to be better absorbed, it requires THC. Without THC, CBDs absorption to the cannabinoid receptors are
dramatically lessened, thus dampening its effectiveness. With many of the consumers not wanting THC in their products, due to various reasons,
including but not limited to intoxicating affects, possible drug testing, and legal repercussions, this currently leaves consumers with having to
choose between taking a CBD product with THC for full effectiveness or to take one without it and not reap the full benefits of CBD. Different
techniques such as water soluble CBD Nano emulsion are being used to allow CBD to become more bioavailable to be absorbed in the blood
stream. So now what is signaling the receptors to absorb the CBD once it gets into the blood stream? How much is being absorbed at a cellular
level?
8
The Solution
CBIO products formulated with GrowthCell's ™ oligopeptide helps to activate the cannabinoid receptors
naturally via acting as a ligand. A ligand that can bind to a receptor can alter the function of the
receptor and trigger a physiological response known as an agonist for that receptor. An agonist binding
to a receptor can be characterized both in terms of how much physiological response can be triggered
and in terms of the concentration of the agonist that is required to produce the physiological response.
An agonist is a chemical that binds to a receptor and activates the receptor to produce a biological
response. Another important benefit to Growth Factors is the ability to activate satellite cells which
also play a vital role in CBD being absorbed 100% without the ligand THC.
Source :https://www.ncbi.nlm.nih.gov/pubmed/21214560
CBD AT THE CELLULAR LEVEL
9. The Proven Benefits
Our first brand to launch, Armourgenix ™, Powered by GrowthCell’s ™ oligopeptide is delivered in an orally administered
supplement that contains chicken embryo extracts, along with many other vital growth factors, vitamins, and synergizing
compounds. Our extraction process utilizes cutting edge science to create a pure, and highly effective product. Each step of the
process is completed in an aseptic, 100% clean environment. When administered daily, this growth factor dietary supplement
creates a host of benefits. (https://www.growthcellglobal.com/the-oligopeptide-growth-factor-dietary-supplement-patent-your-
questions-answered/)
These Benefits Include:
➢ Anti-oxidation
➢ Anti-Inflammation
➢ Improved Metabolic Disorders
➢ Muscle Production and Fat Burning
➢ Enhanced Libido
➢ Adrenal Regulation
➢ High Bioavailability
A recent study found he human volunteers experienced no adverse effects and the apothecary mixtures may be administered by
direction of a flight surgeon for inflammation, joint pain and recovery from injury, stress or anxiety. The raw data as analyzed
shows an increase in CBD blood concentrations of 96.1 to 122.9ng/mL at 60mins with the effector oligopeptide (GrowthCell) and
CBD and blood concentrations of 45.7 to 82.6ng/mL without the effector oligopeptide (GrowthCell ™).
9CBD AT THE CELLULAR LEVEL
10. Armourgenix ™
Armourgenix ™ Sport Supplements are professionally formulated with the patented pharmaceutical
grade extract GrowthCell ™ oligopeptide and pharmaceutical grade Water-Soluble CBD.
➢ Armourgenix ™ Pre-Workout Formula with 600mg Pharmaceutical Grade Water Soluble CBD
The pre-workout formula contains Phytic Acide, Rhodiola Rosea Creatine mono, Fulvic/Humic Acid, Caffeine, CoQIO, GrowthCell oligopeptide,
Pharmaceutical Grade Water Soluble CBD. It is a bio-stimulator with a rapid effect to help the restoration of the energy balance in the human
body. The effect delivers you natural energy to maximize your performance levels along with longer sustained endurance levels, improved
recovery.
➢ Armourgenix ™ Active for Men with 600mg Pharmaceutical Grade Water Soluble CBD
Formula contains patented pharmaceutical grade extract GrowthCell ™ oligopeptide, Pharmaceutical Grade Water Soluble CBD, Fulvic/Humic Acid
and BCAA.
➢ Armourgenix ™ Active for Women with 600mg Pharmaceutical Grade Water Soluble CBD
Formula contains patented pharmaceutical grade extract GrowthCell ™ oligopeptide, Pharmaceutical Grade Water Soluble CBD, Fulvic/Humic Acid
and BCAA, DIM.
10CBD AT THE CELLULAR LEVEL
11. Capital Raise
Our initial capital raise is $1.25M that
will fund early stage operations:
➢Branding for each product vertical
➢Distribution Marketing Campaign
➢Reverse merger with Brunswick
Resources a Canadian publicly traded
company
➢Inventory of GrowthCell ™
formulated products
➢Build a strong cash flow-positive
business
11
Allocation of Raised $ Estimated CND$
Capital Exp., Operations, Licensing & Start-up Cost $500,000.00
RTO Costs & Associated Disbursements $75,000.00
Working Capital for Business Operations $500,000.00
Distributor Media Marketing Campaign $175,000.00
Total Initial Equity Raise $1,250,000.00
CBD AT THE CELLULAR LEVEL
12. Management Team
Shane Lowry
Founder & Director
Mr. Lowry brings extensive business experience having been involved in Canadian and US listed public
companies for over 20 years as both an Officer and Director. He has acted to provide corporate
governance, project financing, and management for varying company sectors.
In addition, Mr. Lowry has brought his extensive knowledge and experience in marketing, product
branding and distribution to both the private and public sectors.
Having a passion for and seeing an opportunity in the thriving Cannabis sector has brought Mr. Lowry to
now co-create CBIO Brand Development, Inc.
Michael Young
Chief Financial Officer
Mr. Young is currently Chief Financial Officer and a director of Harrys Manufacturing Inc. (CSE:HARY). In
his capacity as Chief Financial Officer, Mr. Young reports to the CEO and Board of Harrys regarding all
strategic and tactical matters as they relate to budget management, cost-benefits analysis, forecasting
needs and securing adequate funding.
Mr. Young has over 20 years of extensive business experiences in all facets of corporate development,
senior management, sales, marketing, finance and operations, in both the private and public sectors. His
experience includes spearheading growth strategies, financial reporting, quarterly and annual budgets
and overseeing corporate administration while achieving company objectives.
During his time, Mr. Young has raised over $100 Million from all projects by way of debt and equity to
accomplish growth objectives.
Mr. Young completed the Certified Financial Planning (CFP) Program in 2004.
12
Lisa Little
Founder & President
Miss Little has 12 years of experience in marketing and sales where she developed a passion for
creating consumer confidence and satisfaction through foreseeing the needs of her clients and
exceeding their expectations.
As an entrepreneur, Miss. Little saw the change in regulation that the 2018 Farm Bill has provided
created an opportunity for her to enter the retail wellness and therapeutic product sectors.
Miss. Little will use her learned skills in marketing and communication to propel the sale of the Life Style
products she has co-created and will work closely with the Science Team to produce new formulas
based on consumer feedback.
Glenn Little
Director
Mr. Little brings extensive business, corporate development, and over 26 years of public company
experience to the company. Mr. Little was CEO/President and Director of Brigade Resource Corp.
(formerly Brigadier Resource Corp.) from March 2015 to July 2017. As CEO of Brigade Resource Corp.,
he completed the RTO of Green 2 Blue Energy Corp. and started trading on December 28, 2018.
Mr. Little was the CEO, CFO and a Director of Laguna Blends Inc (CSE: LAG now Isodiol International CSE:
ISOL) from December 2014 until October 2015 and previously provided corporate development services
for the company starting September 2014. He also previously served as CEO, CFO and President of
Corporate Development for Draft Team Fantasy Sports (CSE: DFS) from 2006 until 2012.
Mr. Little was a founder of Stream Communications Network & Media Inc., a cable vision provider
which raised approximately $20 Million USD in debt and equity financing and where he served as
director for same from 1993 – 2005.
CBD AT THE CELLULAR LEVEL
13. Research & Development Team
Dr. Hyder A Khoja, PhD, MSc
Founding Member & VP of Research and Product Development
Dr. Khoja; is an elocutionist philosopher, a visionary entrepreneur & a business savvy. He has had a distinguished professional career, within the high
technology realms with strong adaptive ability in leading diverse regulatory programs combined with functional expertise in science and policy domains. He
enjoys a comprehensive knowledge of both the pharmaceutical and dietary supplements. His extensive industrial experience spans from advising, innovating
& developing cutting-edge projects. He led multidisciplinary teams consisting of Professionals-Engineers, Scientists, and Planners. While working with them;
he built a foundation of strong cross-functional skills including Research & Business development. He has been instrumental in advising to the board for
several private and publicly traded start-up companies. As an honorary bases, Dr. Khoja also serves as a visiting faculty for the Aga Khan University-where he
is helping the Dept. Of Biomedical Sciences to develop pharmacological application through plant and other natural based compounds, since then he has
been a liaison for many educational and industrial cooperative programs. He has held various Executive Research Management positions at other
biotechnology companies where he was involved in researching natural products and plant-based compounds for unmet medical needs. In 2010, he founded
'LeoFric Consultants, Inc., which help design highly targeted knowledge-based solutions to address the global client's challenges. Early in 2014, he Co-
Founded InMed Pharmaceuticals (CSE-IN) and directed Botanical Drug Research and Development for their pre-clinical stage novel therapies into the
extensive pharmacological application, which then became public and raised multi-million dollars in market capital. In 2015, he joined Affinor, Inc (CSE-AFI),
as a VP of Innovation and Scientific affairs where helped in promoting vertical farming system and have made significant progress to get collaboration from
USDA. At present, he is serving as a Chief Scientific Officer, at Qualis Cannabis Corp & Northernroots Labs. Prior to this he served as a Chief Scientific Officer
of NASH Pharmaceuticals, Inc., and helped develop IP focused on (NAFLD) a chronic health condition. Before, joining NASH Pharma, Dr. Khoja served as Chief
Scientific Officer and key advisor at Oceanix Biotechnology Corp where he oversaw global research & development of natural product derived from marine
biomass and therapeutic compounds. He has shown through his vast experience that he is creative, innovative and a have growth expertise both in privately
held or publicly traded companies. He now serves on multiple companies as a Chief Scientific Advisor and on directive board to help develop novel therapies
through the R&D into the extensive pharmacology to develop new and unique (APIs), Active Pharmaceutical Ingredients. Dr. Khoja earned his PhD, with
honors in “Molecular Biology and Genetic Engineering” from a French Ivy league: INP-ENSAT. He had his Post-doctoral training from the Michigan State
University a US land grant university. Soon after, he was appointed as a Research Faculty for Virginia-Tech, University of Wyoming & Texas-Tech University-
Health Science Center, respectively. His breakthrough research work on "Algae 4 Fuel" was recognized by the US-DOE (Department of Energy) and raised
over $50 million. A prolific author, Dr. Khoja published numerous articles, reviews and books on pharmacological research during his over 18 years of
professional career in health industry, focusing on Nutraceuticals and pharmaceutical. In 2011, his work was honored by the United Nation's-FAO. He is an
elocutionist philosopher and has a command over 12 international languages.
CBD AT THE CELLULAR LEVEL 13
14. Share Structure
Proposed Public Offering CSE
Q2 – 2019, Min/Max, $1M/$1.25M @
$0.10/unit
Min/Max 10M – 12.5M units
Each unit consisting of one common
share and one common share purchase
warrant
Each full warrant can be exercised at a
price of $0.25 for two full years
Proposed Business Combination
TSX.V Company
9,776,104 million shares
CBIO Brand Development Inc.
6,900,000 million shares
Fully Diluted Post Private Placement
29,176,104 million shares
CBD AT THE CELLULAR LEVEL 14
